A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

NCT02906202 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Beta-Thalassemia

Interventions

GENETIC: LentiGlobin BB305 Drug Product

Sponsor

Genetix Biotherapeutics Inc.